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The incidence of cardiac death is higher among patients
receiving dialysis compared with the general population.
Although obstructive coronary artery disease is involved
in cardiac deaths in the general population, deaths in
hemodialysis patients occur in the apparent absence of
obstructive coronary artery disease. To study this further, we
prospectively enrolled 155 patients receiving hemodialysis
after angiography had confirmed the absence of obstructive
coronary lesions. All patients were examined by single-
photon emission computed tomography using the iodinated
fatty acid analog, BMIPP, the uptake of which was graded in
17 standard myocardial segments and assessed as summed
scores. Insulin resistance was determined using the
homeostasis model assessment index of insulin resistance
(HOMA-IR). During a mean follow-up of 5.1 years, 42 patients
died of cardiac events. Stepwise Cox hazard analysis
associated cardiac death with reduced BMIPP uptake and
increased insulin resistance. Patients were assigned to
subgroups based on BMIPP summed scores and HOMA-IR
cutoff values for cardiac death of 12 and 5.1, respectively,
determined by receiver operating characteristic analysis.
Cardiac death-free survival rates at 5 years were the lowest
(32.2%) in the subgroup with both a summed score and
assessment equal to or above the cutoff values compared
with any other combination (52.9–98.7%) above, equal to, or
below the thresholds. Thus, impaired myocardial fatty acid
metabolism and insulin resistance may be associated with
cardiac death among hemodialysis patients without
obstructive coronary artery disease.
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Cardiac diseases have an important role in the death of
patients with end-stage renal disease (ESRD) who undergo
renal replacement therapy: 43, 34 and 33% of all-cause
mortality in the United States,1 the United Kingdom,2 and
Japan,3 respectively, are due to cardiac diseases. The incidence
of cardiac death is higher among patients on dialysis4
compared with the general population. Although obstructive
coronary artery disease (CAD) is undoubtedly involved in
cardiac deaths induced by acute myocardial infarction (MI)
or congestive heart failure (CHF) and in sudden cardiac
death (SCD),5–7 cardiac death occurs in patients on
hemodialysis in the apparent absence of extant obstructive
CAD. A recent analysis found that the 5-year cumulative
incidence values of cardiac death among patients on
hemodialysis were 48.3 and 40.2%, respectively, in patients
with and without prior CAD, although not all patients had
undergone coronary angiography (CAG).8 However, few
studies have attempted to clarify which factors are involved in
the cardiac death of hemodialysis patients without obstruc-
tive CAD.
We recently showed that visualizing impaired myocardial
fatty acid metabolism on images could help to detect CAD in
hemodialysis patients.9 Such visualization could identify
those at high risk of cardiac death among asymptomatic
patients on hemodialysis who have not been treated
by coronary intervention or who have no history of MI10
and among those with coronary revascularization achieved
by percutaneous coronary artery intervention (PCI).11 In
addition, the combination of impaired cardiac fatty acid
metabolism on images with insulin resistance, which is a risk
factor related to CAD, might contribute to left ventricular
dysfunction in hemodialysis patients.12 Impaired myocardial
fatty acid metabolism and insulin resistance, both of which
reduce the synthesis of myocardial adenosine triphosphate
(ATP),13–19 are likely to be involved in fatal cardiac events by
causing a deficiency in the myocardial energy supply. Here,
we prospectively investigated the potential of myocardial
fatty acid imaging and insulin resistance to stratify the risk
for cardiac death among patients on hemodialysis who
do not have extant obstructive CAD. We performed dual
single-photon emission computed tomography (SPECT)
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using iodine-123-b-methyl iodophenyl-pentadecanoic acid
(BMIPP) as a fatty acid analog and 201Thallium (Tl) as a
myocardial perfusion tracer to identify reduced myocardial
perfusion due to causes such as unrecognized old MI without
obstructive CAD.
RESULTS
We followed up 155 enrolled patients through to the end
points or to the end of the study for a mean duration of
5.1±2.0 years.
Cardiac events and baseline characteristics
Of the 155 enrolled patients, 42 (27.1%) died of cardiac
events (7 acute MI, 18 CHF, and 17 SCD) and 21 (13.5%)
died of non-cardiac causes (6 malignancy, 4 infectious
diseases, 4 cerebrovascular accidents, 2 respiratory diseases,
2 hepatic diseases, 1 gastrointestinal bleeding, 1 ischemic
colitis, 1 drowning) during follow-up. Acute MI developed in
10 patients. After the onset of acute MI, three patients died
without coronary revascularization and seven underwent
emergency CAG and ad hoc PCI, but four died of cardiac
death within 24 h after PCI. Angina pectoris with significant
electrocardiographic changes developed in eight patients in
whom repeated CAG did not uncover any significant
coronary lesions. Ventricular arrhythmias (Lown grade 3 or
more) were identified in 12 patients, and cardiac death
occurred in 4 (3 SCD and 1 acute MI); the incidence of
ventricular arrhythmia did not differ between patients with
or without cardiac death (9.5 versus 7.1%; P¼ 0.639). The
mean values showed that patients who died of cardiac events
were older, and had higher homeostasis model assessment
index of insulin resistance (HOMA-IR) values and summed
scores for BMIPP or Tl, but a lower body mass index (BMI)
and left ventricular ejection fraction (LVEF) than those who
did not (Table 1a). The mean cardiothoracic ratio tended to
be larger, and the mean serum phosphorus concentration and
the mean product of serum calcium and phosphorus tended
to be lower in the patients with, than without, cardiac death.
However, the groups did not significantly differ in terms
of mean values for dialysis duration, systolic or diastolic
blood pressure, Kt/Vurea, blood hemoglobin concentration,
left ventricular mass index, serum concentrations of albumin,
calcium, total cholesterol, intact parathyroid hormone, high-
sensitivity C-reactive protein, or hemoglobin A1c, plasma
B-type natriuretic peptide concentration, and ratios of male
sex, diabetes mellitus, smoking habit, alcohol consumption,
Table 1a | Baseline clinical characteristics for cardiac death
Cardiac death (+) (n=42) Cardiac death () (n=113) P-value
Age, years 68.7±10.4 61.9±10.3 o0.001
Male gender, n (%) 23 (54.8) 66 (58.4) 0.822
Dialysis duration, months 98.9±111.6 87.4±91.8 0.648
Smoking habit, n (%) 14 (33.3) 46 (40.7) 0.514
Alcohol consumption, n (%) 12 (28.6) 48 (42.5) 0.163
History of congestive heart failure requiring hospitalization, n (%) 16 (38.1) 28 (24.8) 0.127
History of cerebrovascular accidents requiring hospitalization, n (%) 7 (16.7) 12 (10.6) 0.356
Diabetes mellitus, n (%) 15 (35.7) 44 (38.9) 0.856
Hypertension, n (%) 30 (71.4) 74 (65.5) 0.480
Dyslipidemia, n (%) 5 (11.9) 13 (11.5) 0.946
Kt/Vurea 1.78±0.28 1.80±0.21 0.875
Systolic blood pressure before dialysis, mmHg 142.2±14.9 144.3±16.2 0.470
Diastolic blood pressure before dialysis, mmHg 77.1±21.7 79.7±15.7 0.422
Body mass index, kg/m2 19.8±4.3 21.8±4.2 0.011
Cardiothoracic ratio, % 53.5±5.7 51.6±5.0 0.054
Left ventricular ejection fraction, % 59.1±18.0 64.9±12.9 0.028
Left ventricular mass index, g/m2 133.7±36.2 142.8±53.3 0.307
Atrial fibrillation, n (%) 8 (19.1) 19 (16.8) 0.753
Blood hemoglobin, g/dl 10.3±0.9 10.5±1.2 0.386
Serum albumin, g/dl 3.7±0.3 3.8±0.4 0.162
Serum calcium, mg/dl 9.0±0.6 9.0±0.7 0.972
Serum inorganic phosphorus, mg/dl 5.0±1.0 5.4±1.0 0.079
The product of serum calcium and phosphorus, (mg/dl)2 44.9±10.8 48.3±10.3 0.085
Serum total cholesterol, mg/dl 166.1±30.1 170.0±35.4 0.527
Serum intact parathyroid hormone, pg/ml 222.8±144.2 237.9±193.1 0.646
Serum hs-CRP, mg/dl 0.351±0.307 0.394±0.289 0.428
Plasma B-type natriuretic peptide, pg/ml 336.0±326.5 330.7±244.9 0.913
Serum hemoglobin A1c, % 5.9±0.9 (n=15) 5.9±0.6 (n=44) 0.842
HOMA-IR, mg/dl mU/ml 6.3±1.8 4.3±1.6 o0.001
BMIPP summed score 18.1±6.5 6.4±7.0 o0.001
Tl summed score 7.3±4.1 3.4±4.1 o0.001
Abbreviations: BMIPP, iodine-123-b-methyl iodophenyl-pentadecanoic acid; HOMA-IR, the homeostasis model assessment index of insulin resistance; hs-CRP, high-sensitivity
C-reactive protein; Tl, 201Thallium.
Hypertension was defined as administration of antihypertensive medication and/or systolic blood pressure before dialysis ofX140mmHg or diastolic blood pressure before
dialysis of X90mmHg. Dyslipidemia was defined as administration of statins and/or serum total cholesterol concentrations of X220mg/dl.
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hypertension, dyslipidemia, atrial fibrillation, and history of
CHF or cerebrovascular accidents (Table 1a), or prescribed
cardiovascular medications (Table 1b).
Cardiac death and risk analysis
Univariate Cox hazard analysis showed that age, cardiothor-
acic ratio, HOMA-IR, and BMIPP or Tl summed scores were
positively, and BMI, LVEF, and serum albumin concentration
were inversely associated with cardiac death, whereas alcohol
consumption, serum inorganic phosphorus concentrations,
and the product of serum calcium and phosphorus tended to
be associated with cardiac death (Table 2). Hypertension,
dyslipidemia, Kt/Vurea, atrial fibrillation, and a history of
CHF or cerebrovascular accidents were not associated with
cardiac death. Multivariate Cox hazard analysis showed that
cardiac death was positively associated with age, HOMA-IR,
Table 1b |Medications for cardiac death
Cardiac death
(+) (n=42)
Cardiac death
() (n=113) P-value
a1-Blockers, n (%) 4 (9.5) 10 (27.4) 0.853
b-Blockers, n (%) 14 (33.3) 25 (22.1) 0.222
Calcium blockers, n (%) 13 (31.0) 31 (27.4) 0.817
ACEI, n (%) 1 (2.4) 3 (2.7) 0.656
ARB, n (%) 12 (28.6) 27 (23.9) 0.698
Nitrates, n (%) 5 (11.9) 17 (15.0) 0.811
Antiplatelet drugs, n (%) 23 (54.8) 61 (54.0) 0.925
Anticoagulation drugs, n (%) 1 (2.4) 0 (0) 0.650
Statins, n (%) 6 (14.3) 28 (24.8) 0.236
Vitamin D, n (%) 21 (50.0) 70 (61.9) 0.182
Abbreviations: ACEI, angiotensin I-converting enzyme inhibitors; ARB, angiotensin II
type-1 receptor antagonists; SPECT, single-photon emission computed tomography.
Antiplatelet drugs were administered in 24 patients to protect coagulation
of dialyzer during hemodialysis, in 22 patients with peripheral arterial disease, in
14 patients with a history of cerebrovascular accidents, and in 24 patients who had
severely reduced uptake of BMIPP in SPECT, indicating the presence of myocardial
ischemia by microvessel disease.9,10,12
Table 2 | Univariate Cox hazard analysis for cardiac death
Hazard ratio 95% CI P-value
Age (1 year) 1.056 1.027-1.086 o0.001
Gender (0=female; 1=male) 0.871 0.476–1.594 0.655
Dialysis duration (1 month) 1.001 0.998–1.004 0.489
Smoking (0=no; 1=yes) 0.759 0.401–1.438 0.400
Alcohol (0=no; 1=yes) 0.568 0.292–1.107 0.098
History of congestive heart failure requiring hospitalization (0=no; 1=yes) 1.599 0.857–2.983 0.140
History of cerebrovascular accidents requiring hospitalization (0=no; 1=yes) 1.780 0.788–4.019 0.165
Diabetes mellitus (0=no; 1=yes) 0.959 0.512–1.798 0.898
Hypertension (0=no; 1=yes) 1.166 0.596–2.278 0.654
Dyslipidemia (0=no; 1=yes) 0.813 0.319–2.075 0.665
Kt/Vurea (1) 0.713 0.181–2.803 0.628
Systolic blood pressure before dialysis (1mmHg) 0.991 0.972–1.010 0.352
Diastolic blood pressure before dialysis (1mmHg) 0.989 0.967–1.011 0.325
Body mass index (1 kg/m2) 0.919 0.856–0.987 0.021
Cardiothoracic ratio (1%) 1.062 1.005–1.122 0.033
Left ventricular ejection fraction (1%) 0.979 0.961–0.997 0.024
Left ventricular mass index (1 g/m2) 0.998 0.991–1.004 0.451
Atrial fibrillation (0=no; 1=yes) 1.154 0.534–2.493 0.716
Blood hemoglobin (1 g/dl) 0.895 0.696–1.151 0.390
Serum albumin (1 g/dl) 0.430 0.189–0.981 0.046
Serum calcium (1mg/dl) 0.976 0.622–1.530 0.915
Serum inorganic phosphorus (1mg/dl) 0.760 0.564–1.023 0.072
The product of serum calcium and phosphorus (1 (mg/dl)2) 0.971 0.942–1.002 0.063
Serum total cholesterol (1mg/dl) 0.996 0.987–1.00 0.367
Serum intact parathyroid hormone (1 pg/ml) 0.999 0.998–1.001 0.738
Serum hs-CRP (1mg/dl) 0.623 0.209–1.854 0.397
Plasma B-type natriuretic peptide (1 pg/ml) 1.000 0.999–1.001 0.905
Serum hemoglobin A1c (1%) 0.998 0.479–2.079 0.995
HOMA-IR (1mg/dl mU/ml) 1.521 1.332–1.736 o0.001
BMIPP summed score (1) 1.092 1.066–1.118 o0.001
Tl summed score (1) 1.146 1.087–1.207 o0.001
a1-Blockers (0=no; 1=yes) 0.974 0.350–2.715 0.961
a1-Blockers (0=no; 1=yes) 1.583 0.836–2.999 0.161
Calcium blockers (0=no; 1=yes) 1.131 0.589–2.70 0.714
ACEI (0=no; 1=yes) 0.897 0.125–6.448 0.914
ARB (0=no; 1=yes) 1.294 0.664–2.519 0.451
Nitrates (0=no; 1=yes) 0.695 0.275–1.761 0.446
Antiplatelet drugs (0=no; 1=yes) 1.041 0.568–1.908 0.897
Anticoagulation drugs (0=no; 1=yes) 2.792 0.386–20.179 0.312
Statins (0=no; 1=yes) 0.584 0.247–1.381 0.223
Vitamin D (0=no; 1=yes) 0.672 0.367–1.232 0.199
Abbreviations: ACEI, angiotensin I-converting enzyme inhibitors; ARB, angiotensin II type-1 receptor antagonists; BMIPP, iodine-123-b-methyl iodophenyl-pentadecanoic acid;
CI, confidence interval; HOMA-IR, homeostasis model assessment index of insulin resistance; hs-CRP, high-sensitivity C-reactive protein; Tl, 201Thallium.
Hypertension was defined as administration of antihypertensive medication and/or systolic blood pressure before dialysis ofX140mmHg or diastolic blood pressure before
dialysis of X90mmHg. Dyslipidemia was defined as administration of statins and/or serum total cholesterol concentrations of X220mg/dl.
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and BMIPP summed score, and inversely with BMI (Table 3).
The HOMA-IR findings indicated that cardiac death was
associated with fasting plasma concentrations of insulin
(hazard ratio, 1.104; Po0.001), but not with those of glucose
(hazard ratio, 1.013; P¼ 0.218). The mean BMIPP summed
scores did not differ among the types of cardiac death (acute
MI, 14.3±4.9; CHF, 17.9±6.1; SCD, 19.8±7.0). Figure 1
shows three examples of dual BMIPP and Tl SPECT images
from patients who died of acute MI, CHF, or SCD. We
determined cutoff values for cardiac death of 12 for the
BMIPP summed score and 5.1 for HOMA-IR from receiver
operating characteristic (ROC) analysis. The areas under the
ROC curves were 0.916 and 0.808, respectively. Kaplan–Meier
analysis showed that rates of cardiac death-free survival were
lower in patients with HOMA-IR X5.1 than in those with
valueso5.1 (Figure 2a), and were also lower in patients with
BMIPP summed scores of X12 than in those with scores
o12 (Figure 2b). To further investigate the involvement of
myocardial fatty acid metabolism and insulin resistance in
cardiac death, the participants were classified based on the
cutoff values for respective HOMA-IR and BMIPP summed
scores as follows: subgroup 1, o5.1 and o12, (n¼ 81);
subgroup 2, X5.1 and o12 (n¼ 18); subgroup 3, o5.1 and
X12, (n¼ 16); subgroup 4,X5.1 andX12 (n¼ 40). Cardiac
death occurred in 1 patient in subgroup 1 (1 acute MI), 2 in
subgroup 2 (1 CHF and 1 SCD), 8 in subgroup 3 (1 acute MI
and 7 SCD), and 31 in subgroup 4 (5 acute MI, 17 CHF, and
9 SCD). Kaplan–Meier survival estimates showed that the
rates of cardiac death-free survival at 5 years were 98.7, 88.2,
52.9, and 32.2% in subgroups 1, 2, 3, and 4, respectively.
Rates of cardiac death-free survival were lower in subgroup 2
than 1 (Kaplan–Meier analysis, P¼ 0.025), and in subgroup 4
than 3 (Kaplan–Meier analysis, P¼ 0.045) (Figure 3). The
BMIPP summed scores and HOMA-IR positively correlated
and many cardiac deaths were distributed among patients
with BMIPP summed scores of X12 and HOMA-IR X5.1
(Figure 4). The LVEF inversely correlated with BMIPP
summed score (r¼0.272, P¼ 0.001) or HOMA-IR
(r¼0.295, Po0.001). The mean LVEF was lower
(P¼ 0.004) in subgroup 4 than 1 (56.6±18.1 versus
66.7±11.7%), but did not significantly differ among
subgroups 1, 2 (61.6±13.8%), or 3 (64.5±14.2%).
DISCUSSION
Of 155 hemodialysis patients in whom CAG did not identify
obstructive CAD, 42 died of cardiac-related causes during a
5.1±2.0-year follow-up. As 21 of the participants died of
non-cardiac causes, cardiac death accounted for two-thirds of
all-cause deaths among patients without obstructive CAD on
hemodialysis. Stepwise Cox hazards analysis showed that
cardiac death was positively associated with age, BMIPP
summed score, or HOMA-IR, and inversely with BMI.
Kaplan–Meier survival estimates revealed that event-free rates
of cardiac death worsened when summed BMIPP scores or
HOMA-IR were above the cutoff values of 12 or 5.1,
respectively, as determined by ROC analysis. The cardiac
Table 3 |Multivariate Cox hazard analysis for cardiac death
Hazard ratio 95% CI P-value
Age (1 year) 1.033 1.010–1.067 0.045
Body mass index (1 kg/m2) 0.931 0.868–0.998 0.044
BMIPP summed score (1) 1.059 1.025–1.099 o0.001
HOMA-IR (1mg/dl mU/ml) 1.298 1.101–1.530 0.002
Abbreviations: BMIPP, iodine-123-b-methyl iodophenyl-pentadecanoic acid;
CI, confidence interval; HOMA-IR, homeostasis model assessment index of insulin
resistance.
Vertical
long axis
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Figure 1 | Iodine-123-b-methyl iodophenyl-pentadecanoic acid (BMIPP)- and 201Thallium single-photon emission computed
tomography (Tl SPECT) images from patients who died of cardiac events. (a) A 63-year-old diabetic woman with summed BMIPP and Tl
scores of 16 and 6, respectively, died of acute myocardial infarction 63 months after SPECT. Homeostasis model assessment index of insulin
resistance (HOMA-IR) was 5.2 and left ventricular ejection fraction was 58%. Emergency coronary angiography showed severe stenosis (99%) of
left anterior descending artery (no. 6). This patient died during ad hoc percutaneous coronary intervention. (b) Non-diabetic 71-year-old man
with summed BMIPP and Tl scores of 24 and 12, respectively, who died of congestive heart failure 30 months after SPECT. His HOMA-IR was 8.9
and left ventricular ejection fraction was 77%. (c) Non-diabetic 75-year-old woman with summed BMIPP and Tl scores of 18 and 8, respectively,
who died of sudden cardiac event 32 months after SPECT. HOMA-IR was 5.4 and left ventricular ejection fraction was 75%. Repeated coronary
angiography at 28 months after SPECT because of chest pain during dialysis did not reveal significant obstructive coronary lesions.
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death-free survival rate was lowest in the subgroup with a
BMIPP summed score of X12 and HOMA-IR of X5.1.
Myocardial fatty acid metabolism on images and insulin
resistance were independently associated with the cardiac
death of hemodialysis patients without obstructive CAD.
Further, coexisting impaired myocardial fatty acid imaging
and advanced insulin resistance apparently comprise a
powerful predictor of cardiac death in this population.
A decrease in myocardial fatty acid metabolism semi-
quantitatively assessed using BMIPP SPECT in patients
without obstructive CAD would indicate the involvement
of a disordered myocardial microvasculature. Studies using
positron emission computed tomography that can accurately
measure absolute myocardial blood flow have shown that
coronary flow reserve is reduced before plaque lesions or
luminal stenoses became apparent on invasive angiograms or
multislice computed tomograms.20,21 Among patients with-
out significant obstructive CAD, endothelium-dependent
vasodilation was less evident in a group with, than without,
reversible perfusion defects on myocardial perfusion
images.22 Reduced coronary flow reserve or a myocardial
microcirculatory disturbance would thus be attributed to
vascular endothelial dysfunction.
Insulin resistance is a common feature of patients with
ESRD23 and is linked with vascular endothelial dysfunc-
tions.24–26 Endothelial damage caused by insulin resistance
appears to have particularly significant effects on small
arterioles. Jaap et al.27 reported an association between
insulin sensitivity and microvascular function in non-
diabetic individuals with fasting hyperglycemia. Serne
et al.28 reported that microvascular function, as assessed by
laser Doppler flowmetry, is associated with insulin sensitivity
100
80
60
40
20
0
0 1 2 3 4 5 6 7 8
Years
0 1 2 3 4 5 6 7 8
Years
Su
rv
iva
l p
ro
ba
bi
lity
 (%
)
100
80
60
40
20
0
Su
rv
iva
l p
ro
ba
bi
lity
 (%
)
BMIPP summed score  12
BMIPP summed score  12
HOMA-IR  5.1
HOMA-IR  5.1
a
b
Figure 2 |Kaplan–Meier analysis of cardiac death-free survival
rates. (a) Event-free survival rates of cardiac death at 5 years are
49.6 and 91.8% for patients with homeostasis model assessment
index of insulin resistance (HOMA-IR) of X5.1 and o5.1,
respectively. Log-rank test, Po0.0001. (b) Event-free survival
rates of cardiac death at 5 years are 38.8 and 96.8% when
iodine-123-b-methyl iodophenyl-pentadecanoic acid (BMIPP)
summed scores are X12 and o12, respectively. Log-rank test,
Po0.0001.
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Figure 3 |Kaplan–Meier analysis of cardiac death-free survival
rates by iodine-123-b-methyl iodophenyl-pentadecanoic acid
(BMIPP) summed score and homeostasis model assessment
index of insulin resistance (HOMA-IR). Subgroup 1, HOMA-IR
o5.1 and BMIPP summed score o12, n¼ 81; subgroup 2, X5.1
ando12, n¼ 18; subgroup 3,o5.1 andX12, n¼ 16; subgroup 4,
X5.1 andX12, n¼ 40. Cardiac death-free survival rates are lower
in subgroup 2 than in 1 (P¼ 0.025) and in subgroup 4 than in 3
(P¼ 0.045). Kaplan–Meier survival estimates revealed that event-
free rates of cardiac death at 5 years were 98.7, 88.2, 52.9, and
32.2% in subgroups 1, 2, 3, and 4, respectively.
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Figure 4 |Correlation between iodine-123-b-methyl
iodophenyl-pentadecanoic acid (BMIPP) summed score and
homeostasis model assessment index of insulin resistance
(HOMA-IR). Patients with (K) and without (J) cardiac death.
Kidney International (2011) 79, 363–371 367
M Nishimura et al.: Risk of cardiac death on hemodialysis o r ig ina l a r t i c l e
even in healthy individuals. In addition, glucose-clamp-
derived indices of insulin resistance closely correlate with
coronary vascular function assessed by Doppler blood flow
ultrasonography in individuals with unobstructed coronary
arteries.29 As the hearts of patients with ESRD have
anatomically abnormal microcirculation, such as fewer
myocardial capillary vessels or increased myocardial fibro-
sis,30–33 endothelial dysfunction linked with insulin resistance
is likely to worsen this condition in hemodialysis patients.
Under normal, unstressed conditions, the heart predomi-
nantly metabolizes free fatty acids (FFA) (B70% of ATP
production).13 In the setting of insulin resistance, circulating
levels of FFA increase and myocardial fatty acid metabolism
becomes upregulated.34–37 When the FFA supply exceeds the
oxidative capacity of the heart, FFAs become stored as
intramyocardial triglycerides that are associated with lipo-
toxicity and a worsening cardiac function.13–15 Increased FFA
levels associated with insulin resistance promote the synthesis
of uncoupling proteins that dissipate the proton gradient
across the inner mitochondrial membrane, resulting in the
production of heat rather than ATP and a reduction in ATP
synthesis.16–19 Further, the oxygen supply to myocardial cells
does not seem to be sufficient for increased FFA oxidation in
patients on hemodialysis with insulin resistance, as insulin
resistance causes microangiopathy through endothelial dys-
functions24–29,38 and patients with ESRD generally have a
microcirculatory disturbance in the heart30–33 as noted above.
Myocardial ATP synthesis would be reduced in patients with
insulin resistance who are on hemodialysis.
On the other hand, the metabolism of myocardial FFA is
decreased and that of glucose is increased in the injured or
failing heart through an adaptive response, which maximizes
the efficiency of ATP synthesis.39 Myocardial fatty acid
metabolism in the mitochondria is reportedly inhibited
during the early phase of cardiac dysfunction without heart
failure induced by cardiac pacing, despite normal coronary
blood flow.40 Stressed conditions such as continued pressure
and/or volume overload to the heart might shift myocardial
energy synthesis from fatty acid oxidation to glucose
oxidation.39,41,42 Thus, myocardial fatty acid metabolism
could be suppressed and replaced by glucose metabolism in
patients on chronic hemodialysis who have continued
pressure and/or volume overload to the heart.
Insulin resistance combined with impaired myocardial
fatty acid metabolism will cause an obvious reduction in
myocardial ATP synthesis in patients on hemodialysis, even if
the epicardial coronary arteries are free of stenotic lesions.
The BMIPP summed scores correlated with HOMA-IR, and
many cardiac deaths occurred in the subgroup with a higher
HOMA-IR and a higher BMIPP summed scores. On the
other hand, LVEF inversely correlated with BMIPP summed
scores or HOMA-IR, and the mean LVEF was lowest in the
subgroup with a higher HOMA-IR and a higher BMIPP
summed scores. Insulin resistance and impaired myocardial
fatty acid metabolism might be closely connected and lead to
myocardial dysfunction among patients on hemodialysis who
do not have obstructive CAD. The coexistence of insulin
resistance and impaired myocardial fatty acid metabolism is
422 Hemodialysis patients who had received
coronary angiography (CAG) between 1 January
2001 and 31 December 2004
23 Patients:
Excluded
Excluded
Enrolled: 155 hemodialysis patients
(89 men, 66 women; 64 ± 11 years)
Follow-up: through 31 December 2008
205 Patients without stenotic coronary lesions
27 Patients:
1) Patients who had not measured HOMA-IR within
    1 month after CAG (n = 8)
2) Patients receiving extrinsic insulin or medication of 
    sulfonylurea (n = 19)
1) Patients who had not done BMIPP–TI SPECT within
    1 month of CAG (n = 6)
2) Congestive heart failure (New York Heart Association
    grades III–IV; n = 5)
3) Significant valvular heart disease (n = 4)
4) Pacemaker (n = 2)
5) Pulmonary disease (n = 2)
6) Idiopathic hypertrophic or dilated cardiomyopathy (n = 3)
7) Malignancy (n = 1)
Figure 5 | Entry and exclusion of study participants.
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thought to result in an extreme reduction in myocardial ATP
synthesis, which might elicit left ventricular dysfunction up
to fatal CHF, malignant arrhythmias up to SCD, or severe
myocardial damage up to death on acute MI.
This study has several limitations. We used CAG to
confirm the presence of suspected myocardial ischemia.
‘Without significant obstructive CAD’ does not necessarily
mean that the epicardial coronary arteries are normal. As
histopathological and intravascular ultrasound studies have
demonstrated the propensity of angiography to under-
estimate lesional severity,43,44 we cannot exclude the
possibility that some angiographically nonsignificant lesions
were flow limiting. We used HOMA-IR to evaluate levels of
insulin resistance. Although others have shown that HOMA-
IR closely correlates with clamp-measured insulin resistance
in patients with or without diabetes mellitus,45–47 including
those with chronic renal failure,48 the use of HOMA-IR can
be considered as a limitation of this study. The proportion of
statin use was low, whereas that of antiplatelet drugs
was high. These characteristics of our study population
might have influenced the incidence of cardiac death. As our
study cohort was relatively small, we could not define
the predictive value of BMIPP SPECT or HOMA-IR for
cardiac death. A larger patient population is needed to
establish the clinical implications and prognostic value of
these parameters.
This study uncovered two novel findings. First, cardiac
death occurs at a high incidence among patients on
hemodialysis who do not have evident obstructive CAD.
The absence of significant epicardial coronary lesions in CAG
does not necessarily mean that cardiac death occurs at a low
frequency among this population. Second, coexisting insulin
resistance and impaired myocardial fatty acid metabolism
evaluated by HOMA-IR and BMIPP SPECT might indicate a
considerable risk for cardiac death in hemodialysis patients
without obstructive CAD. Myocardial fatty acid imaging by
BMIPP SPECT is thought to be unique compared with other
traditional risk factors, as it reflects myocardial ATP content
and directly expresses cardiac energy status. As myocardial
ATP synthesis would be significantly reduced by insulin
resistance with coexisting impaired myocardial fatty acid
metabolism, a deficiency in the myocardial energy supply
might have an important role in the occurrence of cardiac
death among this population. Investigating disordered
myocardial energy metabolism in hemodialysis patients,
regardless of obstructive CAD, should help to elucidate the
mechanism of cardiac death including SCD.
METHODS
Patients
Figure 5 summarizes the entry and exclusion criteria for the study,
which proceeded at three dialysis centers associated with the
Toujinkai Group.
Eligibility criteria included patients on hemodialysis without
obstructive CAD according to CAG, who had been assessed by
BMIPP–Tl dual SPECT, and whose HOMA-IR was determined as a
parameter of insulin resistance. A total of 422 patients with ESRD on
maintenance hemodialysis at the Toujinkai Group underwent CAG
for the first time to determine the presence or absence of CAD
between 1 January 2001 and 31 December 2004. Most of the patients
had been examined by BMIPP–Tl dual SPECT within 1 month
before the first CAG. Significant stenotic coronary lesions (diameter
of stenosis 450%) were not identified in 205 of the 422 patients.
The HOMA-IR was measured in these patients without significant
stenotic coronary lesions within 1 month after the first CAG,
as described below. Among them, 23 were excluded based on the
following: no BMIPP–Tl SPECT examination within 1 month before
CAG (n¼ 6), CHF of NYHA (New York Heart Association) grades
III–IV (n¼ 5), moderate or worse valvular heart disease (n¼ 4:
Sellers III and IV aortic regurgitation, Sellers III mitral regurgitation,
and Sellers III mitral stenosis; n¼ 1 each), permanent pacemaker
implantation (n¼ 2), pulmonary diseases (n¼ 2), idiopathic
cardiomyopathy (n¼ 3), and malignancy at the time of CAG
(n¼ 1). We also excluded patients whose HOMA-IR had not been
measured within 1 month after CAG (n¼ 8) and those who had
been receiving extrinsic insulin or sulfonylurea medication to treat
diabetes (n¼ 19). Patients were not included in the study if they had
a history of acute MI or invasive coronary artery intervention such
as coronary artery bypass grafting or PCI, or unrecognized old MI
without obstructive CAD identified as significantly reduced uptake
on Tl SPECT images. Consequently, 155 hemodialysis patients
without significant obstructive coronary lesions were enrolled in this
study (89 men and 66 women; mean age, 64±11 years;
mean dialysis duration, 91±97 months). The study participants
were enrolled at the time of the HOMA-IR measurements
(between 1 January 2001 and 31 December 2004) and followed up
through to 31 December 2008, until the end point described below
was reached.
The causes of renal failure among the enrolled patients were
chronic glomerular disease in 54.8% (85/155), diabetes mellitus in
38.1% (59/155), polycystic kidney disease in 3.2% (5/125),
nephrosclerosis in 3.2% (5/155), and gout kidney in 0.6% (1/155)
of patients. All enrolled patients with type II diabetes mellitus had
been treated before starting hemodialysis, but they had received
neither extrinsic insulin nor sulfonylurea for at least 6 months
before starting this study. Their mean values for serum hemoglobin
A1c, fasting plasma glucose, and immunoreactive insulin were
5.9±0.7%, 99±14 (69–144) mg/dl, and 20.1±7.9 (6.3–54.5) mU/ml,
respectively, and that for mean HOMA-IR was 4.8±1.9 mg/dl  mU/
ml (1.5–9.9 mg/dl  mU/ml). Blood pressure was measured hourly
during dialysis using a mercury sphygmomanometer and deter-
mined as the mean of all measurements obtained during dialysis
sessions over a period of 2 weeks before CAG. Cardiothoracic ratios
and BMI were measured before starting the first hemodialysis
session of the week within 1 month before CAG. A history of
cigarette smoking or alcohol consumption was determined from a
questionnaire. The Ethics Committee for Human Research of the
Toujinkai Group approved the study protocol, and all patients
provided written, informed consent to participate in all procedures
associated with the study.
Coronary angiography
Experienced interventional cardiologists performed quantitative
CAG at the Department of Interventional Cardiology of the Kyoto
Second Red Cross Hospital using a validated automated edge-
detection program (CCIP-310/W, CATHEX, Tokyo, Japan). Sig-
nificant coronary artery stenosis is defined as stenosis of 450%
diameter on CAG images.
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Radionuclide imaging
All patients underwent resting BMIPP and Tl dual SPECT after
fasting for over 6 h within 1 month before the first CAG. Details of
the dual BMIPP–Tl SPECT procedure are described elsewhere.9–12
The images were divided into 17 segments for semiquantitative
analysis according to the standard myocardial segmentation for
tomographic heart imaging established by the American Heart
Association.49 The amount of radioactivity uptaken by each segment
was visually graded and assigned uptake scores of 0 (normal),
1 (mildly reduced), 2 (moderately reduced), 3 (severely reduced),
and 4 (none). The BMIPP and Tl SPECT scores for 17 myocardial
segments were designated as summed BMIPP and Tl scores,
respectively. All BMIPP and Tl SPECT images were interpreted
within 1 week of the SPECT examination by the same two
investigators who were blinded to clinical and laboratory informa-
tion about the patients. The interobserver and intraobserver
variability in the summed scores at our institute were 6.8±1.4
and 5.4±1.4%, respectively. In this study, the summed scores were
significantly correlated between the interpretations by two different
observers (r¼ 0.950, Po0.001, n¼ 155) and between the two
different interpretations by the same observer (r¼ 0.982, Po0.001,
n¼ 155).
Echocardiography
The patients underwent two-dimensionally guided echocardiogra-
phy using a single ultrasonographic recorder (UF-8800, Fukuda
Denshi, Tokyo, Japan) within 1 month before CAG. Left ventricular
dimensions and LVEF were quantified using the biplanar Simpson’s
rule, and left ventricular mass was measured as recommended by
the American Society of Echocardiography.50 Left ventricular mass
was normalized to body surface area, and is described herein as left
ventricular mass index.
Biochemical and hematological determinations
On a midweek dialysis day within 30 days after CAG, blood samples
(10 ml) were obtained in the morning from patients who had fasted
overnight and rested for 10 min. Hemoglobin (and hemoglobin
A1c for diabetic patients), plasma concentrations of intact
parathyroid hormone and plasma B-type natriuretic peptide, and
serum concentrations of calcium, inorganic phosphorus, albumin,
total cholesterol, and high-sensitivity C-reactive protein were
determined.
Assessment of insulin resistance
We used fasting plasma glucose and fasting plasma insulin
concentrations to calculate the HOMA-IR value described by
Mathew et al.45 as fasting glucose concentration (mg/dl)  fasting
insulin concentration (mU/ml)/405. Blood samples were collected
on the same day to measure other biochemical and hematological
parameters.
End point
The end point was cardiac-derived death, that is, SCD or death due
to acute MI or CHF. We defined SCD as death within 24 h of the
time that the patient was last seen alive in a normal state of health,
and for which cardiac diseases such as malignant arrhythmias or
acute coronary syndrome were considered the cause. Cerebrovas-
cular accidents were ruled out by postmortem examinations. Acute
MI was diagnosed when new abnormal Q-waves appeared on
electrocardiograms together with anterior chest pain or discomfort,
when abnormal left ventricular wall motion was recognized on
echocardiograms, and when serum concentrations of troponin-T
and creatine phosphokinase-MB fraction were significantly elevated.
Blinded investigators within the Toujinkai group or Kyoto Second
Red Cross Hospital adjudicated all end points.
Statistical analysis
Values are expressed as means±s.d. We compared the means of
continuous variables using nonpaired t-tests. Categorical data were
analyzed using the w2-test. Thresholds for the BMIPP summed score
and HOMA-IR for cardiac death were defined using ROC analysis;
thresholds were obtained from minimal false-positive and
false-negative results, that is, by minimizing the expression
(1specificity)2þ (1sensitivity)2. Prognosis was assessed using
univariate and multivariate Cox proportional hazards models.
Covariates that were significant in univariate Cox hazard analyses
(Po0.1) were assessed by multivariate Cox hazards analyses. We
examined event-free survival using the Kaplan–Meier method and
the log-rank test. P-values of o0.05 were considered significant. All
data were statistically analyzed by individuals who were blinded to
any clinical information about the patients.
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